Abstract | BACKGROUND:
Giant cell tumor (GCT) is usually a benign but locally aggressive primary bone neoplasm in which monocytic macrophage/osteoclast precursor cells and multinucleated osteoclast-like giant cells infiltrate the tumor. The etiology of GCT is unknown, however the tumor cells of GCT have been reported to produce chemoattractants that can attract osteoclasts and osteoclast precursors. Rarely, GCT can originate at extraosseous sites. More rarely, GCT may exhibit a much more aggressive phenotype. The role of chemotherapy in metastatic GCT is not well defined. CASE PRESENTATION: CONCLUSION:
|
Authors | Keith M Skubitz, J Carlos Manivel |
Journal | BMC cancer
(BMC Cancer)
Vol. 7
Pg. 46
(Mar 14 2007)
ISSN: 1471-2407 [Electronic] England |
PMID | 17359524
(Publication Type: Case Reports, Journal Article, Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibiotics, Antineoplastic
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Alkylating
- Bevacizumab
- Doxorubicin
- Ifosfamide
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage)
- Antibiotics, Antineoplastic
(administration & dosage)
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Alkylating
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bevacizumab
- Combined Modality Therapy
- Doxorubicin
(administration & dosage)
- Female
- Giant Cell Tumors
(diagnosis, drug therapy, surgery)
- Humans
- Hysterectomy
- Ifosfamide
(administration & dosage)
- Lung Neoplasms
(diagnosis, drug therapy, secondary)
- Middle Aged
- Treatment Outcome
- Uterine Neoplasms
(diagnosis, drug therapy, surgery)
|